论文部分内容阅读
目的:对硝苯地平联合厄贝沙坦片治疗原发性高血压的临床疗效进行探讨和分析。方法:选取我院于2012年1月-2013年12月间收治的100例原发性高血压患者资料患者资料,按照临床治疗方式的不同分为实验组与对照组各50例;其中,为对照组患者提供硝苯地平治疗,为实验组提供硝苯地平联合厄贝沙坦治疗。经过相同治疗周期,对两组患者血压、心率变化情况及治疗效果相关数据进行统计,并展开对比。结果:实验组硝苯地平联合厄贝沙坦片对于原发性高血压患者血压的调控有效性较高,经治疗血压收缩压、舒张压分别由(164.5±10.5)mmgHg、(105.3±8.8)mmHg下降到(124.7±6.8)mmHg、(73.0±5.5)mmHg,对照组由治疗前(161.0±11.2)mmgHg、(106.2±7.8)mmHg下降到(135.2±6.2)mmHg、(78.6±4.8)mmHg,差异具有显著性(P<0.05);两组治疗有效性分别为44(88%)、34(68%),P<0.05。两组患者治疗前后心律均未表现出显著性变化(P>0.05)。结论:硝苯地平联合厄贝沙坦片对于原发性高血压患者血压调控效果较好,临床治疗作用优于单纯硝苯地平治疗,值得临床推广使用。
Objective: To investigate and analyze the clinical efficacy of nifedipine combined with irbesartan tablets in the treatment of essential hypertension. Methods: The data of 100 patients with essential hypertension treated in our hospital from January 2012 to December 2013 were selected and divided into experimental group and control group according to the different clinical treatment methods. Among them, Patients in the control group were treated with nifedipine and nifedipine combined with irbesartan in the experimental group. After the same treatment cycle, the two groups of patients with blood pressure, heart rate changes and treatment-related data statistics, and contrast. Results: The experimental group nifedipine combined with irbesartan tablets for the control of blood pressure in patients with essential hypertension is more effective, the treatment of systolic blood pressure, diastolic blood pressure were (164.5 ± 10.5) mmgHg, (105.3 ± 8.8) mmHg decreased to (124.7 ± 6.8) mmHg and (73.0 ± 5.5) mmHg respectively in the control group from (161.0 ± 11.2) mmHg and (106.2 ± 7.8) mmHg to (135.2 ± 6.2) mmHg and (78.6 ± 4.8) mmHg (P <0.05). The effective rates of the two groups were 44 (88%) and 34 (68%) respectively, P <0.05. Before and after treatment, the two groups showed no significant changes in heart rate (P> 0.05). Conclusion: Nifedipine combined with irbesartan tablets has a good effect on blood pressure control in patients with essential hypertension. The clinical effect of nifedipine and irbesartan tablets is better than that of nifedipine alone. It is worthy of clinical promotion.